Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Neuroendocrine Tumors, Version 1.2015 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., Goldner, W. S., Halfdanarson, T. R., Heslin, M. J., Kandeel, F., Kunz, P. L., Kuvshinoff, B. W., Lieu, C., Moley, J. F., Munene, G., Pillarisetty, V. G., Saltz, L., Sosa, J. A., Strosberg, J. R., Vauthey, J., Wolfgang, C., Yao, J. C., Burns, J., Freedman-Cass, D. 2015; 13 (1): 78-108

Abstract

Neuroendocrine tumors (NETs) comprise a broad family of tumors that may or may not be associated with symptoms attributable to hormonal hypersecretion. The NCCN Clinical Practice Guidelines in Oncology for Neuroendocrine Tumors discuss the diagnosis and management of both sporadic and hereditary NETs. This selection from the guidelines focuses on sporadic NETs of the pancreas, gastrointestinal tract, lung, and thymus.

View details for Web of Science ID 000347793200012

View details for PubMedID 25583772